John Wilkinson
Noxopharm Limited, NSW, Australia
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
Novel drug (CRO-67) in commercial pipeline have both anti-tumour and stromal reprogramming capacity (#108)
1:00 PM
Shannon Chiang
Lunch & Poster Viewing (Even Numbers)